Key Inclusion Criteria:

• Laboratory-confirmed SARS-CoV-2 infection as determined by polymerase chain reaction (PCR) or other commercial or public health assay
• Hospitalized with illness of any duration with evidence of pneumonia and severe disease, critical disease, or multi-system organ dysfunction at baseline
• Ability to provide informed consent signed by study patient or legally acceptable representative
• Willingness and ability to comply with study-related procedures/assessments

Key Exclusion Criteria:

• In the opinion of the investigator, unlikely to survive for >48 hours from screening
• Presence of any of the following abnormal laboratory values at screening: absolute neutrophil count (ANC) less than 2000 mm3, aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than 5 x upper limit of normal (ULN), platelets <50,000 per mm3
• Treatment with anti-IL 6, anti-IL-6R antagonists, or with Janus kinase inhibitors (JAKi) in the past 30 days or plans to receive during the study period
• Current treatment with conventional synthetic disease-modifying antirheumatic drugs (DMARDs)/immunosuppressive agents
• Use of chronic oral corticosteroids for a non-COVID-19-related condition in a dose higher than prednisone 10 mg or equivalent per day
• History of, or current autoimmune or inflammatory systemic or localized disease(s) other than rheumatoid arthritis
• Known active tuberculosis (TB), history of incompletely treated TB, suspected or known extrapulmonary TB, suspected or known systemic bacterial or fungal infections
• Patients who have received immunosuppressive antibody therapy within the past 5 months, including intravenous immunoglobulin or plans to receive during the study period
• Participation in any clinical research study evaluating an investigational product (IP) or therapy within 3 months and less than 5 half-lives of IP prior to the screening visit (The use of remdisivir in the context of a single-arm remdisivir compassionate use protocol is permitted)
• Any physical examination findings and/or history of any illness that, in the opinion of the study investigator, might confound the results of the study or pose an additional risk to the patient by their participation in the study
• Other protocol defined inclusion / exclusion criteria may apply